Biohaven's deal with SK Biopharmaceuticals for Kv7 and opakalim rights resolves a key near-term capital overhang - William Blair
Biohaven will certainly now generate significantly more near-to-mid-term cash from the launch, than it would have if it launched itself - TD Cowen
Including session's moves, BHVN up ~32% YTD
Biohaven shares rise on epilepsy licensing deal
Shares of drugmaker Biohaven BHVN.N rise 5.4% to $15.15
Biohaven enters a partnership with South Korean drug maker SK Biopharmaceuticals 326030.KS worth up to $795 million to license and commercialize a new epilepsy drug platform
SK Biopharmaceuticals gains exclusive global rights to Biohaven's lead epilepsy drug candidate, opakalim
Opakalim is in mid-to-late stage trial testing for focal epilepsy, and trial results are expected in H2 2026
Biohaven to use SK's established epilepsy development and sales network to bring opakalim to patients globally
BHVN•
